Soleno Therapeutics Files 8-K on Operations
Ticker: SLNO · Form: 8-K · Filed: 2024-08-07T00:00:00.000Z
Sentiment: neutral
Topics: 8-K, financial-reporting, operations
TL;DR
SOLENO filed an 8-K on Aug 7th covering operations & financials. Details TBD.
AI Summary
On August 7, 2024, Soleno Therapeutics, Inc. filed an 8-K report. The filing primarily concerns the company's results of operations and financial condition, along with financial statements and exhibits. No specific financial figures or operational updates were detailed in the provided text, but the filing indicates a report date of August 7, 2024.
Why It Matters
This 8-K filing serves as an official notification to the SEC and investors regarding Soleno Therapeutics' operational and financial status, which could impact stock valuation.
Risk Assessment
Risk Level: low — The filing is a standard 8-K for operational and financial reporting, with no immediate negative or positive news indicated in the provided text.
Key Players & Entities
- Soleno Therapeutics, Inc. (company) — Registrant
- August 7, 2024 (date) — Report Date
- Delaware (jurisdiction) — State of Incorporation
- Capnia, Inc. (company) — Former Company Name
FAQ
What specific financial results or operational updates are detailed in this 8-K filing?
The provided text of the 8-K filing does not detail specific financial results or operational updates; it only indicates that the filing pertains to 'Results of Operations and Financial Condition' and includes 'Financial Statements and Exhibits'.
When was this 8-K report filed by Soleno Therapeutics, Inc.?
The 8-K report was filed on August 7, 2024, which is also the earliest event reported date.
What is the principal executive office address for Soleno Therapeutics, Inc.?
The principal executive offices are located at 203 Redwood Shores Pkwy, Suite 500, Redwood City, CA 94065.
What was Soleno Therapeutics, Inc. formerly known as?
Soleno Therapeutics, Inc. was formerly known as Capnia, Inc., with a date of name change on February 19, 2010.
Under which section of the Securities Exchange Act of 1934 is this 8-K report filed?
This 8-K report is filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
Filing Stats: 504 words · 2 min read · ~2 pages · Grade level 11.8 · Accepted 2024-08-07 17:18:30
Key Financial Figures
- $0.001 — ange on which registered Common Stock, $0.001 par value SLNO NASDAQ Indicate by
Filing Documents
- d892011d8k.htm (8-K) — 24KB
- d892011dex991.htm (EX-99.1) — 81KB
- g892011g07x51.jpg (GRAPHIC) — 10KB
- 0001193125-24-196040.txt ( ) — 243KB
- slno-20240807.xsd (EX-101.SCH) — 3KB
- slno-20240807_lab.xml (EX-101.LAB) — 18KB
- slno-20240807_pre.xml (EX-101.PRE) — 11KB
- d892011d8k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. SOLENO THERAPEUTICS, INC. Date: August 7, 2024 By: /s/ Anish Bhatnagar Anish Bhatnagar Chief Executive Officer